Danaher Corporation $DHR Shares Newly Acquired by Navigate Wealth Management LLC

Navigate Wealth Management LLC purchased a new stake in Danaher Corporation (NYSE:DHR) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 11,507 shares of the conglomerate’s stock, valued at approximately $2,549,000. Danaher accounts for about 1.5% of Navigate Wealth Management LLC’s portfolio, making the stock its 16th biggest position.

Other large investors have also recently bought and sold shares of the company. EP Wealth Advisors LLC acquired a new stake in shares of Danaher during the second quarter worth $3,807,000. Puzo Michael J bought a new stake in shares of Danaher in the second quarter valued at about $8,624,000. First Nebraska Trust Co bought a new stake in shares of Danaher in the second quarter valued at about $14,106,000. Madison Asset Management LLC acquired a new position in shares of Danaher in the second quarter valued at about $85,451,000. Finally, Colton Groome Financial Advisors LLC acquired a new position in shares of Danaher in the third quarter valued at about $592,000. 79.05% of the stock is owned by institutional investors.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Danaher Price Performance

Shares of DHR traded up $1.63 during trading hours on Wednesday, hitting $224.47. 1,984,723 shares of the company were exchanged, compared to its average volume of 4,449,140. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a market cap of $157.80 billion, a price-to-earnings ratio of 39.83, a P/E/G ratio of 2.78 and a beta of 0.76. The firm’s fifty day moving average is $212.41 and its 200 day moving average is $195.13.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.77 earnings per share. On average, equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Evercore reaffirmed an “outperform” rating and set a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. The Goldman Sachs Group lifted their price target on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Finally, Morgan Stanley lifted their price target on shares of Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.